Rezolute, Inc.
For the period ended Jun 30, 2025. Filed Sep 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Sep 17, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| | ||
|---|---|---|
| · Page | ||
| Part I | | |
| | | |
| Item 1. Business | | 1 |
| | | |
| Item 1A. Risk Factors | | 6 |
| | | |
| Item 1B. Unresolved Staff Comments | | 17 |
| | | |
| Item 1C. Cybersecurity | | 17 |
| | | |
| Item 2. Properties | | 18 |
| | | |
| Item 3. Legal Proceedings | | 18 |
| | | |
| Item 4. Mine Safety Disclosures | | 18 |
| | | |
| Part II | | |
| | | |
| Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | | 18 |
| | | |
| Item 6. [Reserved] | | 19 |
| | | |
| Item 7. Management’s Discussion and Analysis of Financial Condition and Result of Operations | | 19 |
| | | |
| Item 7A. Quantitative and Qualitative Disclosures About Market Risk | | 27 |
| | | |
| Item 8. Financial Statements and Supplementary Data | | 28 |
| | | |
| Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | | 60 |
| | | |
| Item 9A. Controls and Procedures | | 60 |
| | | |
| Item 9B. Other Information | | 61 |
| | | |
| Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections | | 61 |
| | | |
| Part III | | |
| | | |
| Item 10. Directors, Executive Officers and Corporate Governance | | 62 |
| | | |
| Item 11. Executive Compensation | | 62 |
| | | |
| Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | | 62 |
| | | |
| Item 13. Certain Relationships and Related Transactions, and Director Independence | | 62 |
| | | |
| Item 14. Principal Accounting Fees and Services | | 62 |
| | | |
| Part IV | | |
| | | |
| Item 15. Exhibits and Financial Statement Schedules | | 62 |
| | | |
| | | |
| Signatures | | 66 |
-i-
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K for the fiscal year ended June 30, 2025 (“Annual Report”) contains statements reflecting assumptions, expectations, projections, intentions or beliefs about future events that are intended as “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included or incorporated by reference in this Annual Report, other than statements of historical fact, that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements appear in a number of places, including, but not limited to “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements represent our reasonable judgment of the future based on various factors and using numerous assumptions and are subject to known and unknown risks, uncertainties and other factors that could cause our actual results and financial position to differ materially from those contemplated by the statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts, and use words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “may,” “should,” “plan,” “project” and other words of similar meaning. In particular, these include, but are not limited to, statements relating to the following:
| ● | our ability to obtain regulatory approvals for our therapeutics in development; |
| ● | our expectations regarding clinical development and the timeline to complete clinical studies; |
| ● | our projected operating or financial results, including anticipated cash flows to be used in operating activities; |
| ● | our expectations regarding capital expenditures, research and development (“R&D”) expenses and the timing of milestone payments required under license agreements; |
| ● | our beliefs and assumptions relating to our liquidity position, including our ability to obtain additional financing; |
| ● | our future dependence on third-party manufacturers or strategic partners to manufacture any of our pharmaceutical drugs and diagnostics that receive regulatory approval; and |
| ● | our ability to identify strategic partners and enter into license, co-development, collaboration or similar arrangements. |
Any or all of our forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks, uncertainties and other factors including, but not limited to, the risks described in “Risk Factors” in Part I, Item 1A of this Annual Report.
In addition, there may be other factors that could cause our actual results to be materially different from the results referenced in the forward-looking statements, some of which are included elsewhere in this Annual Report, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Many of these factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. Our future results may vary materially from those expressed or implied in any forward-looking statements. All forward-looking statements contained in this Annual Report are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are made, and we disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date of this Annual Report, except as otherwise required by applicable law.
-ii-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.